Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment
NCT03309202
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatic Impairment
Interventions
DRUG:
PF-05221304
Sponsor
Pfizer